The short version: The Wolverine stack combines BPC-157 and TB-500, two research peptides that are often studied together for tissue repair applications. Both are sold as research-use-only laboratory chemicals, not medications, and both were placed in FDA Category 2 of bulk drug substances that may present significant safety risks in 2023. No published study has evaluated the combination as a formulation. Before ordering, verify the supplier’s lot-specific certificate of analysis, confirm the testing laboratory is independent, and check that the listing maintains a strict research-use-only boundary. Stack Research publishes lot-specific documentation for its BPC-157 and TB-500 research peptides.
Search for “Wolverine stack peptide for sale” and you will find a market built around a two-peptide combination that has become one of the most recognized stacks in the research peptide category. The name comes from the Marvel character’s healing factor, which is a marketing convention rather than a scientific designation. The two components, BPC-157 and TB-500, have separate research histories and separate mechanisms of action.
This guide is written for laboratory researchers who need to evaluate a Wolverine stack supplier before placing an order. It covers what the published literature says about each component, why the combination has not been studied as a formulation, how to read a certificate of analysis without getting misled, and the specific questions that separate a transparent supplier from one that is hoping you will not ask.
What the Wolverine stack is
The Wolverine stack is a fixed-ratio combination of two peptides: BPC-157 and TB-500. The most common configuration is a 20 mg total vial containing 10 mg of BPC-157 and 10 mg of TB-500, though other ratios are also sold. The blend is supplied as a lyophilized powder labeled for laboratory research use only.
The two components are often discussed together because they are studied for overlapping applications in tissue repair, but they operate through different mechanisms. A physician-authored review of peptide stacks describes BPC-157 as driving angiogenesis and TB-500 as promoting cell migration. The review notes that no study has tested the combination as a formulation.
The individual components: what the research shows
BPC-157: preclinical evidence, no human trials for this indication
BPC-157 is a synthetic pentadecapeptide derived from human gastric juice protein. A review published in Cell and Tissue Research in 2019 examined BPC-157’s role in accelerating musculoskeletal soft tissue healing. The review found that BPC-157 was studied extensively in animal models for tendon, ligament, and muscle repair, but noted that human clinical trial data is lacking.
USADA’s athlete guidance on BPC-157 states plainly that there are no human clinical trials establishing efficacy for any diagnosis or treatment, and that because the compound has not been extensively studied in humans, it is unknown whether there is a safe dose. The British Society for Cutaneous Gerontology’s guidance notes that BPC-157 is prohibited at all times by WADA and that its use poses risks for athletes subject to anti-doping testing.
TB-500: actin regulation and cell migration research
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in actin regulation and cell migration. A review published in Trends in Molecular Medicine described thymosin beta-4 as an actin-sequestering protein that is upregulated in response to tissue injury and plays a role in cell migration and tissue repair.
A study published in the FASEB Journal examined the role of thymosin beta-4 in cell migration and tissue repair. The researchers found that thymosin beta-4 promotes cell migration by regulating actin dynamics. The study concluded that thymosin beta-4 plays a critical role in wound healing, though the research was limited to in-vitro and animal models.
TB-500 is prohibited at all times under the World Anti-Doping Agency’s Prohibited List. USADA’s sanction announcement for triathlete Anthony McCauley stated that McCauley accepted a four-year suspension after testing positive for BPC-157, TB-500, CJC-1295, and ipamorelin.
Why the combination has not been studied
The most important limitation of the Wolverine stack is also the simplest to state: no published study has evaluated the two-peptide combination as a formulation. This means that the interaction between the two peptides, their combined stability in a single lyophilized vial, and their combined effects in any biological system are all unknown from a published-evidence perspective.
Many suppliers present the stack as if its effects are the straightforward sum of its components, which is an assumption that has not been tested. The physician-authored review notes that claims about synergy are extrapolations from separate studies, not findings from combined research.
For researchers, the practical implication is that the Wolverine stack is a novel formulation in the research sense. Any experiment using it is testing a combination that has not been characterized in the published literature.
Video: The truth about the Wolverine stack
This third-party video provides general context on the Wolverine stack. It is not affiliated with Stack Research and is not a substitute for laboratory documentation or the published literature.
The researcher’s verification checklist
The difference between a defensible purchase and a gamble comes down to documentation. Here is what to check, in order.
1. Lot-specific certificate of analysis for the blend, not just the components
A certificate of analysis (COA) is only meaningful if it corresponds to the exact lot you are buying. For a blend, this is more complicated than for a single peptide. The COA should confirm the identity and quantity of each component in the blend, not just the total peptide content.
Stack Research publishes a lot-specific report for its BPC-157 / TB-500 blend research peptide. The current lot documentation shows identity conforms, HPLC purity, and measured content for the 20 mg configuration. The report identifies the testing laboratory as Accumark Labs and includes a report ID that can be cross-referenced.
2. What a blend COA should test
A certificate for a peptide blend should include identity confirmation for each component, purity by HPLC, measured content, endotoxin, and sterility. For the Wolverine stack specifically, the identity confirmation should establish that both peptides are present and match their reference standards.
3. The research-use-only boundary
Every legitimate research peptide supplier uses the research-use-only (RUO) designation. The RUO label means the product is not intended for diagnostic, therapeutic, or human use. It is a legal boundary, not a suggestion. What to watch for is a supplier that uses the RUO label while simultaneously publishing dosing information, before-and-after photos, or customer testimonials about human use.
4. Pricing and configuration transparency
The Wolverine stack is typically sold as a 20 mg vial. The price per milligram of total peptide should be calculable from the listing. Stack Research lists its 20 mg BPC-157 / TB-500 blend at $149.90 with volume pricing available to verified research accounts. The product page shows the exact SKU and lot information alongside the price.
5. Stability and storage considerations
A two-peptide blend introduces stability questions that a single peptide does not. Each component has its own optimal storage conditions, and the blend’s stability as a combined formulation has not been characterized in published literature. The Stack Research peptide storage guide covers handling and storage conditions for lyophilized research peptides.
How Stack Research approaches Wolverine stack documentation
Stack Research is a research peptide supplier that publishes lot-specific documentation for each product configuration. The company’s testing page describes the analytical methods used and the laboratories that perform the work.
The BPC-157 / TB-500 blend product page states explicitly that the cited papers discuss the individual components, not the combined formulation, and that they do not establish the blend’s identity, component interaction, stability, or performance. The COA library collects the reports for all products so that researchers can compare documentation across configurations.
Comparing Wolverine stack documentation standards
| Documentation element | What a complete listing shows | Red flag if missing |
|---|---|---|
| Lot-specific COA | Report tied to the exact lot number, with testing lab named | Generic COA or no lot number |
| Component identity | Each peptide in the blend identified separately | Single identity result for the whole blend |
| Purity by HPLC | Reported for the tested sample, with method stated | Purity percentage only, no method |
| Measured content | Actual total peptide mass, not just label claim | No fill or content verification |
| Endotoxin and sterility | Pass/fail results for both | Omitted entirely |
| Research-use-only boundary | No dosing, administration, or human-use content | Testimonials, before/after photos, influencer dosing content |
| Evidence disclosure | States that components are studied separately, not as a blend | Implies combination effects are established |
| Price transparency | Vial size, price, and SKU visible together | Price hidden behind account creation or minimum order |
Common questions researchers ask about the Wolverine stack
What is the Wolverine stack made of?
The Wolverine stack combines two peptides: BPC-157 and TB-500. The most common configuration is a 20 mg vial containing 10 mg of BPC-157 and 10 mg of TB-500. The blend is sold as a research-use-only laboratory chemical.
Has the Wolverine stack been studied in clinical trials?
No. No published study has evaluated the two-peptide combination as a formulation. The individual components have separate research histories, but the blend itself has not been tested in clinical trials.
What purity should a Wolverine stack COA show?
Purity by HPLC above 95 percent is the typical threshold for research-grade peptides. The purity figure is only meaningful alongside identity and content results. For a blend, the identity confirmation should establish that both peptides are present and match their reference standards.
How do I verify that a Wolverine stack COA is real?
Check that the testing laboratory is named and that the report ID can be cross-referenced. Some laboratories publish verification portals where a report ID can be entered to confirm the document’s authenticity.
What is the difference between the Wolverine stack and the GLOW blend?
The Wolverine stack contains BPC-157 and TB-500. The GLOW blend contains GHK-Cu, BPC-157, and TB-500. The naming reflects the components included. Researchers should confirm the identity of any product by its COA, not by the brand name on the vial.
What should I do if a supplier’s listing makes health claims?
Treat it as a disqualifying signal. Health claims on a research peptide listing are the exact pattern the FDA has cited in warning letters. A supplier that describes what the blend “does” for the body is marketing an unapproved drug, regardless of the research-use label elsewhere on the page.
Important notice: This article is provided for educational and informational purposes only. It does not constitute medical, legal, or regulatory advice. Research peptides discussed here are sold exclusively for laboratory research use and are not approved by the FDA or any other regulatory agency for human or veterinary use. Nothing in this article should be construed as guidance for human consumption, dosing, or administration. Statements regarding dietary supplements and research compounds have not been evaluated by the FDA. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction. Always consult the product label, the certificate of analysis, and a qualified professional before making decisions about any substance.